Red light therapy

Repeated low-level red-light (RLRL) therapy is one of the best-evidenced PBM applications anywhere: across 73 human studies including multiple RCTs, 650 nm RLRL slows axial elongation and myopic shift in children — the landmark Jiang (2021) double-blind RCT (n=264) and a large 600-child trial (Wang 2025) found RLRL comparable to 1% atropine and better than orthokeratology for controlling axial length and spherical equivalent. Efficacy for slowing progression is well supported; the genuinely open issues are durability (rebound after stopping) and long-term retinal safety, where isolated injury reports demand respect.

This is PBM's most robust clinical application. Across a deep human evidence base (146 human studies of 254 total), red-light PBM (typically 660 nm intra-oral) prevents and reduces severe chemo/radiotherapy-induced oral mucositis: a Phase III double-blind RCT showed a six-fold drop in grade 3-4 mucositis (6.4% vs 40.5%; Antunes 2013), with consistent benefit on severity and quality of life across Martins 2020, Silva 2015 and others. The signal is strong and reproducible enough that PBM is endorsed in supportive-care guidelines (MASCC/ISOO).

PBM prophylaxis and treatment significantly reduces severity, incidence of Grade >=3 oral mucositis, and pain in head-and-neck cancer patients undergoing chemoradiotherapy; MASCC/ISOO guideline-endorsed.

This is among PBM's better-supported brain claims: 8 human RCTs plus a meta-analysis (Salehpour 2019) report beneficial effects on cognitive performance in young, healthy individuals, with Barrett & Gonzalez-Lima 2013 showing improved sustained-attention reaction time and delayed-match memory after a single 1064 nm session — backed by animal work linking transcranial light to higher prefrontal oxygen consumption and better memory. The effect is real and replicated, but the meta-analysis flags high heterogeneity, and some single sessions (e.g., Chan 2021) showed no change on certain tasks. Net: moderate confidence, task- and dose-dependent.

A sizable human literature (~43 human studies, several double-blind RCTs, plus reviews) supports low-level laser for dentin hypersensitivity. Gerschman's double-blind RCT showed ~67% thermal-sensitivity reduction vs 17% placebo (p<0.001), and Ko's double-blind RCT of a 635 nm laser-emitting toothbrush cut pain scores significantly more than the LED control (5.8 to 2.3 vs 6.4 to 5.5, p<0.05). Results are consistent enough to call this a real, mechanism-plausible effect, though some head-to-head comparisons against fluoride varnish were a wash (Corona 2003) and protocols differ - best positioned as an effective adjunct.

A substantial human literature (23 studies, including a double-blind RCT by Gupta 1998 where 660+880 nm reduced residual ulcer area to 24.4% vs 84.7% placebo, p=0.0008, and a sham-controlled RCT by Schumann 2011 where wIRA + visible light improved healing, p=0.012) supports PBM/photo-energy as an adjunct that accelerates chronic venous ulcer closure and reduces pain. The evidence is heterogeneous in wavelength and delivery (laser, LED, water-filtered IR-A, even blue light) and trials are mostly small, but the direction is consistently favorable. PBM is an adjunct to compression therapy and wound care - the standard of care - not a replacement.

Acne is one of the better-validated light-therapy indications. In a double-blind RCT, a home blue (420 nm) + red (660 nm) LED device cut inflammatory lesions by 77% and non-inflammatory by 54% with reduced sebum (Kwon 2013); a randomized trial found combined blue-red phototherapy improved inflammatory lesions 76%, beating blue light and benzoyl peroxide (Papageorgiou 2000). Blue light alone reduced lesions ~64% and cut P. acnes in vitro (Kawada 2002), and red light alone reached a 77% response by week 10 (Pinto 2013). The evidence is encouraging and consistent in direction, though wavelengths, devices, and protocols vary widely — best regarded as a real adjunct for mild-to-moderate acne.

Across roughly 11 randomized trials plus non-RCTs and case series, photobiomodulation (largely 633-810 nm intra-oral diode laser) has repeatedly cut pain in burning mouth syndrome, a notoriously refractory neuropathic condition. Bardellini's double-blind RCT (n=85) showed significant symptom and oral-health-QoL gains (p=0.0008), Hanna's cohort dropped VAS pain from 7.6 to 3.9, and Lu's 2025 multicenter RCT reported an ~81% response rate when PBM was paired with oral cryotherapy. This is one of PBM's stronger oral-medicine signals; effect sizes and protocols still vary, and it should be offered as an adjunct rather than a sole therapy.

Alzheimer's is one of PBM's most developed brain indications: preliminary randomized trials report improved cognitive scores (MMSE, MoCA) versus placebo (Nizamutdinov 2021, Qi 2021, Nagy 2021, Chao 2019), backed by a deep mechanistic literature in animal models showing PBM reduces amyloid-beta, shifts microglia from inflammatory M1 to repair M2, restores mitochondrial dynamics, and improves memory. The mechanism-plus-early-human convergence is genuinely promising. Honest limits: the human RCTs are small and preliminary, and the strongest mechanistic detail is still animal — so 'moderate' confidence with confirmation pending.

Controlled human work shows near-infrared PBM genuinely increases microcirculatory blood flow: in a randomized trial, 830 nm over the wrist raised flow by 27% immediately and 54% at 20 minutes (p=0.004), while 633 nm red light did not (Gavish 2020) — and follow-up analysis tied response to baseline skin temperature, with only about half of people responding (Ovadia-Blechman 2023). LED phototherapy (625/660/850 nm) also improved blood flow at chronic-wound edges in a randomized trial (Frangez 2017). This is one of PBM's better-supported vascular effects, but it is wavelength- and person-dependent, and the evidence is for localized delivery, not whole-body beds.

Lateral epicondylitis is one of PBM's better-supported musculoskeletal indications (16+ RCTs, ~28 human studies). Chang's 2010 meta-analysis found significant pain-relief effect sizes (pooled ES 0.71 post-treatment, 1.05 at follow-up) plus grip-strength and ROM gains when laser targeted tender/trigger points, Stergioulas 2007 (sham-controlled, 904 nm) reduced pain when added to exercise, and de Oliveira 2025 (sham RCT) showed a higher responder rate for PBM plus a static magnetic field (72% vs 40%). The convergence of a meta-analysis and consistent RCTs makes this a solid adjunct, with point-targeting and dose mattering.

Myofascial pain syndrome is one of the most-studied PBM indications here (≈19 RCTs, 6 non-RCTs). Most trials applying low-level laser to trigger points report reduced pain and improved range of motion — Demirkol 2015 found LLLT (1064 nm) as effective as occlusal splints and superior to placebo, and Chang 2021 showed immediate relief — though some, like Altan 2005 (904 nm), found no advantage over placebo. The weight of evidence supports trigger-point LLLT as an effective adjunct when dosed correctly, within a broader pain-management plan.

Oral lichen planus has one of the better PBM evidence bases in oral medicine: ~23 human studies including randomized comparisons against the standard, topical corticosteroids. Dillenburg 2014 (660 nm) achieved higher complete-resolution rates than clobetasol with no recurrence at 90 days, Hemanth 2026 reported PBM superior to triamcinolone on pain and lesion severity (VAS p=0.002), and Mutafchieva 2024 showed PBM lowered salivary IL-1-beta, IL-6, and TNF-alpha alongside symptom relief. Consistent, mechanism-backed results make this a genuine steroid-sparing option - still best framed as an adjunct/alternative to be validated by larger trials.

Photobiomodulation has encouraging, fairly consistent human support in burn care. A double-blind RCT showed 655 nm LLLT significantly accelerated healing of skin-graft donor sites in burn patients (Vaghardoost 2018), polarized-light therapy shortened healing of deep dermal burns with almost no hypertrophic scarring (Monstrey 2002), fluorescent light energy healed all 18 acute second-degree burns without adverse effects (Mellergaard 2021), and a striking case series achieved complete healing in 13 diabetic grade-3 burn ulcers that were amputation candidates, using LLLT plus grafting (Dahmardehei 2016). The evidence spans wavelengths and devices but points the same way: PBM is a credible adjunct for burn healing and scar quality.

Photobiomodulation has solid randomized support for preventing acute radiation dermatitis. In the TRANSDERMIS RCT (808+905 nm), PBM significantly reduced skin-reaction severity at the end of radiotherapy (fewer grade 2/3 reactions, p=0.004) (Robijns 2018), and its objective sub-analysis showed moist desquamation in only 7% of the PBM group versus 30% of controls (Robijns 2018). A controlled study (660+805 nm) similarly cut grade 2/3 reactions and pain (Strouthos 2017). One trial using 590 nm LED found no benefit (Fife 2010), highlighting parameter dependence. On balance, the controlled evidence is positive enough for an honest moderate grade, with wavelength/dose clearly mattering.

Plantar fasciitis is well-studied (6+ RCTs, ~20 human studies). Cinar 2017 (sham-controlled, 850 nm) improved function over usual care, Kiritsi 2010 (double-blind, 904 nm) reduced pain and fascia thickness, and Ulusoy 2017 reported the highest success rate for LLLT (70.6%) versus ESWT (65%) and ultrasound (23.5%). A 2026 trial found high-intensity laser no better than sham (both improved with stretching), so the strongest signal is for low-level laser as an adjunct to stretching/orthotics rather than high-intensity protocols alone.

Pressure-ulcer healing is one of the better-supported PBM wound indications: roughly 10 human RCTs plus non-RCTs, with red/NIR (and even blue-light) phototherapy generally improving wound-area reduction versus standard care alone. A sham-controlled RCT of blue-light PBM nearly doubled mean area reduction (52% vs 30%), and red+NIR LED protocols improved healing in pilot RCTs, while animal work shows the effect hinges on getting irradiance/exposure right. The signal is real and clinically meaningful as an adjunct to pressure offloading, wound dressings, and infection control — not a replacement for them.

Several randomized and crossover trials show low-level laser/light reduces the severity and, in some, the frequency of Raynaud attacks: al-Awami 2004 (double-blind RCT, n=47) found significantly greater improvement than placebo, while Hirschl 2002/2004 crossover studies reliably cut attack intensity (to ~82% of baseline) even when frequency was less affected. A single-arm MLS-laser study also showed clinical and microvascular gains. The evidence supports LLLT as a useful adjunct for symptom severity, with effects on attack frequency more variable.

Several randomized trials support PBM for primary dysmenorrhea: Shin 2012 (610 nm, double-blind) reported an 83% pain-reduction rate (p=0.001 over placebo), and a multicenter double-blind RCT (Hong 2016, n=88, 610 nm) showed significantly greater VAS reduction with active light (4.34 vs 1.79, p<0.001) and no serious adverse events; Wang 2023 (630 nm) matched combined oral contraceptives on relief while altering pain-related metabolites. The convergent RCT evidence is moderate and consistent. A well-tolerated, drug-sparing adjunct for menstrual pain - not a replacement for evaluating secondary causes.

Several small human RCTs support PBM as an add-on in wrist/hand (and adjacent) fracture rehab. Chang 2014 (sham-controlled, n=50, 830 nm) improved healing parameters significantly versus placebo, Saebo 2022 (triple-blind, n=50, 904 nm) showed better PRWHE scores and less night pain/analgesic use out to 26 weeks after distal radius fracture, and Baek 2017 documented greater facial-fracture edema reduction (16.5% vs 7.3%, p<0.047). Encouraging and consistent for pain, edema, and function as an adjunct to standard fracture care, though samples are small and protocols vary.

Shoulder pain has a robust PBM literature (17+ RCTs, ~36 human studies). Stergioulas 2008 (sham-controlled, n=63, 810 nm) significantly reduced pain and disability in frozen shoulder, and Santamato 2009 found high-intensity laser superior to ultrasound in subacromial impingement; results are not uniform - Bingol 2005 showed gains in some signs but not pain, and ESWT outperformed LLLT in one comparison. Overall the evidence supports PBM as an effective adjunct (often with exercise) for frozen shoulder and impingement, with device/dose heterogeneity the main caveat.

Allergic rhinitis has a substantial human literature (13+ RCTs, ~30 human studies). Intranasal phototherapy improved nasal symptoms versus placebo (Kennedy & Robertson 2020, sham RCT, n=64), red/infrared PBM improved nasal inspiratory flow and obstruction (Oliveira 2025, RCT, n=62), and rhinophototherapy enhanced quality of life (Cingi 2009). A caveat for biohackers: several effective protocols use mixed UV-visible 'Rhinolight' light (immunomodulatory) rather than classic red/NIR PBM, so mechanism and device matter. Net: a genuinely supported, well-tolerated intranasal option as an adjunct to standard allergy care.

Diabetic neuropathy has one of the deepest human PBM literatures here — 11 RCTs and 8 non-RCTs — and the results are genuinely mixed but lean positive. Yamany 2012 (850 nm, sham-controlled) showed significant pain reduction plus improved electrophysiology and foot microcirculation, and a pilot device study (Rajeswari 2024, 890 nm) reported large nerve-conduction gains; yet Swislocki 2010 found no difference in pain intensity, and Almasi 2025 saw reductions that didn't reach between-group significance. So PBM helps some patients with painful diabetic neuropathy — particularly via microcirculation and nerve conduction — but effects are inconsistent across protocols.

Dry-eye disease has one of the larger ophthalmic PBM evidence bases (24 human studies): LLLT reduced dry-eye symptom (SPEED) scores more than IPL in a randomized comparison (Giannaccare 2023), combined IPL+LLLT lengthened tear break-up time even in Sjogren's patients (Di Marino 2021), and a 460-eye retrospective series showed OSDI and meibomian-gland improvements in patients who had failed conventional therapy (Stonecipher 2019). The direction is consistently positive, but many protocols pair LLLT with IPL, so the standalone PBM effect is partly entangled.

Fibromyalgia has a solid PBM base (≈10 human RCTs), with phototherapy — alone, combined with exercise, or as laser acupuncture — repeatedly lowering pain and improving FIQ/quality-of-life versus controls. da Silva 2017 (double-blind RCT, n=160) found phototherapy plus exercise raised pain thresholds at multiple tender points, and De Lima 2025 (RCT) reported large effects on pain and symptom severity with pulsed laser acupuncture. Whole-body PBM is now being explored qualitatively. The evidence supports PBM as a worthwhile adjunct within multimodal FM care, not a stand-alone fix.

In chronic autoimmune (Hashimoto's) hypothyroidism, near-infrared PBM applied over the thyroid (820-850 nm) has, across several human trials including a sham-controlled RCT (Hofling 2013), reduced levothyroxine requirements (38.6 vs 106.9 microg/day, p<0.001), lowered anti-TPO antibodies and improved gland echogenicity; a 350-patient study (Ercetin 2020) echoed higher T3 and reduced replacement needs. Results are encouraging and mechanism-consistent, though one RCT (Tunc 2024) found no change in thyroid function despite better oxidative-stress markers, so effects are not uniform. Human studies used neck-targeted delivery, not a full-body bed - applying bed delivery is a plausible extension to confirm, not a proven equivalence - and PBM remains an adjunct alongside endocrinology care, never a replacement for levothyroxine.

Multiple randomized trials support PBM for headache, most using low-level laser acupuncture: in children, Gottschling 2008 (double-blind, multicenter) cut headache days by 6.4/month vs 1.0 on placebo (P<0.001); Ebneshahidi 2005 significantly reduced tension-headache intensity and duration; and an ILIB study in migraine improved pain and raised regional cerebral blood flow. The replicated, placebo-controlled signal is encouraging for both migraine and tension-type headache. The main caveat is delivery: most positive trials use laser acupuncture or intravascular irradiation, not a simple topical or full-body protocol.

Multiple randomized trials support PBM for post-cesarean pain: a double-blind RCT (Poursalehan 2018, n=80, 650+804 nm) significantly reduced pain at 1-24 h and total analgesic consumption, and a sham-controlled RCT (de Holanda Araujo 2019, n=88, 660 nm) showed meaningfully larger effect sizes for pain (0.71/0.69 active vs 0.11/0.43 placebo/control). A non-randomized study (Dehghanpour 2023) reported better wound recovery. The convergent RCT evidence is moderate-quality and consistent. PBM is a drug-sparing analgesic adjunct, not a replacement for obstetric/post-op care.

Photobiomodulation for dry AMD has a solid and growing human signal: Merry (2016) reported ~5.9 ETDRS-letter BCVA gains plus contrast-sensitivity and drusen improvements after a 3-week multiwavelength (590/670/790 nm) course, sustained at 3 months, and Nassisi (2024) saw BCVA peak at 12 weeks though it partially regressed by 24 weeks, with two patients developing neovascularization. Preclinical work (Begum 2013, 670 nm) anchors the mechanism in mitochondrial/anti-inflammatory effects. Net: a credible, repeatable functional benefit, with durability and retreatment cadence the open questions.

Recurrent cold sores respond well to PBM in randomized trials. In a double-blind RCT, 690 nm laser extended the median recurrence-free interval to 37.5 weeks versus 3 weeks for placebo (p<0.0001) (Schindl & Neumann 1999); a large randomized comparison found 670 nm LLLT an effective treatment that lengthened recurrence intervals without side effects (Munoz Sanchez 2012); and a recent double-blind RCT showed 940 nm PBM added to acyclovir reduced pain and lesion size faster than acyclovir alone (Seyyedi 2024). The evidence converges on real benefit for recurrence prevention and symptom control, earning an honest moderate grade.

Three human trials point the same general direction: LED (945 nm) beat laser and placebo for radicular pain, claudication and disability when paired with positioning/exercises (de Carvalho 2016); HILT added to collagenase chemonucleolysis accelerated early VAS/ODI/SF-36 recovery (Song 2025); and HILT matched TENS/ultrasound for cervical disc herniation (Yilmaz 2020). The throughline is real benefit for pain and function, but modalities (LLLT vs LED vs HILT), wavelengths and co-interventions vary widely, so the effect is encouraging rather than locked in.

Tooth-extraction recovery is one of PBM's most-studied dental uses (~112 human studies, 20 reviews). Randomized trials show reduced post-extraction pain and complications: Nejat 2021 (double-blind, n=80, 660+810 nm) lowered alveolar osteitis incidence and pain on days 2-5, Intan 2018 showed faster pain decline (905 nm), and Abdel-Alim 2015 found immediate post-op application most effective. The weight of evidence supports PBM as an effective adjunct for post-extraction pain, edema, trismus, and dry-socket prevention, with heterogeneity in wavelength, dose, and timing the main caveat.

Across 19 human studies (including 2 RCTs and 3 controlled non-RCTs), PBM applied to the facial nerve has improved recovery in Bell's palsy — Wu's controlled trial and RCT (808+905 nm) showed significantly better House-Brackmann and Sunnybrook grades at 6 months in patients whose palsy had lasted more than 8 weeks. Adding light to standard care looks like a reasonable, low-risk adjunct, particularly for cases that aren't resolving on their own. Heterogeneous devices and protocols (several use laser acupuncture) keep confidence at moderate rather than high.

PBM reduces pain (VAS) and disability in knee osteoarthritis with moderate-certainty evidence; best results at 904–905 nm or 785–808 nm, 4–8 J/cm2, 10–16 sessions. Overdosing above 4–8 J/cm2 reduces effect.

PBM reduces pain and improves function in tendinopathy across multiple sites; evidence for chronic neck pain is positive in controlled trials, though fewer large RCTs than for OA.

Pre-exercise PBM significantly reduces muscle soreness and fatigue and limits EIMD (reduced CK and oxidative stress); post-exercise PBM improves functional recovery. IOC recognizes PBM for acute muscular recovery.

A meta-analysis of 37 studies and 586 participants found photobiomodulation improved muscle endurance in single-joint exercise (SMD 0.27) and time to exhaustion in cycling (SMD 0.35), with no effect on single-joint strength, running, or swimming performance. The irradiation was applied before exercise as a preconditioning method, which is the opposite of the Superhuman Protocol's placement of red light last.

Achilles tendinopathy has a reasonable PBM base (about 7 human RCTs and 2 non-RCTs). An early large double-blind RCT (n=176) found laser therapy significantly outperformed placebo through one-month follow-up, with the biggest gains in acute tendinitis. The body of evidence supports LLLT as a useful adjunct — most convincing for acute presentations and when dosed correctly — within a rehab program rather than as a stand-alone treatment.

For pattern hair loss, low-level laser/light therapy has the most robust evidence in PBM dermatology. Four pooled multicenter, double-blind, sham-controlled RCTs (269 subjects) with a 655 nm laser comb showed a statistically significant increase in terminal hair density in both men and women, with no serious adverse events (Jimenez 2014) — this device class is FDA-cleared. A randomized double-blind trial of a 650 nm home helmet likewise improved hair density and diameter versus sham (Suchonwanit 2018), and further RCTs combining red/green LED with microneedling show added benefit (Charoensuksira 2024). The honest grade is solidly moderate: consistent, controlled, reproducible gains — tempered by device heterogeneity and some industry funding.

LLLT/PBM devices (630–680 nm; comb/helmet/cap) significantly increase hair density vs. sham in androgenetic alopecia; combination with topical minoxidil is superior to minoxidil alone.

Low back pain has a large PBM literature (~49 human studies) with honestly conflicting results. Multiple RCTs are positive - Konstantinovic 2010 (n=546, 904 nm) and Vallone 2014 (980 nm, delta-VAS 3.96 vs 2.23) showed added benefit, often combined with NSAIDs or exercise - yet Guimaraes 2021, a well-designed double-blind RCT (n=148), found PBM no better than placebo for chronic nonspecific LBP. The fairest read: PBM may help as part of a multimodal program, especially in acute/radicular or inflammatory presentations, but it is not a reliable standalone fix and the best-controlled evidence tempers enthusiasm.

Multiple randomized trials support PBM for breastfeeding nipple pain/trauma: Coca 2016 (660 nm, double-blind) cut pain by about 2.0 cm at 24 h (p=0.016), Gaitero 2026 (660+808 nm, n=60) showed significant pain relief from 30 min through days post-treatment, and Chaves 2012 (860 nm LED) significantly improved both lesion healing (p<0.001) and pain (p<0.001). The pain-relief evidence is consistent and moderate-quality; effects on healing are positive but less uniform across trials. PBM is a painless adjunct that may help sustain breastfeeding - combined with latch/technique support, not a replacement.

PBM (660 nm red, 590 nm amber) reduces periocular wrinkle volume ~30% vs. sham over 10 sessions, with histological evidence of increased Type I collagen and decreased metalloproteinases.

PBM accelerates healing and reduces wound size in diabetic and chronic wounds, with positive effects across inflammation, proliferation, and maturation phases; diverse device types show consistent directional benefit.

PBM as adjunct to lifestyle intervention modestly reduces BMI (-1.18), body weight (-3.54 kg), and waist circumference (-7.28 cm) vs. control in obese patients (11 RCTs, n=569); fat mass % and waist-to-hip ratio were NOT significantly improved. Standalone consumer 'fat-melting' claims are not supported (D).

PBM consistently reduces local and peripheral inflammatory markers at targeted sites (TNF-a, IL-1b, IL-6, CRP up to ~40%). Systemic whole-body anti-inflammatory benefit from consumer panels is mechanistically plausible but NOT established by large RCT (D-level).

Several RCTs report better sleep with PBM: transcranial 810 nm improved PSQI and Epworth scores with EEG delta changes in chronic insomnia (Mehdizadeh 2025), an 830 nm laser array improved PSQI/insomnia scores and quality of life in night-shift nurses (Lin 2025), and whole-body red light improved sleep in athletes. Effects can be conditional — Giménez 2023 saw benefits (mood, drowsiness) only at 6.5 J/cm² and only in winter, and Zhao 2022 found no between-group sleep-efficiency difference. Net: a generally positive, mechanism-plausible signal across both transcranial and whole-body delivery, best treated as an adjunct for sleep.

The flagship ELATED-2 RCT (Cassano 2018) found a sizable antidepressant effect of transcranial NIR (823 nm) in MDD (HAM-D17 effect size 0.75-1.5), and open/retrospective multi-watt NILT series report high response/remission rates — but the larger ELATED-3 trial did not confirm benefit, and an SAD light-visor RCT suggested even infrared light helps. Strong animal models (Salehpour 2019) show PBM reduces depressive-like behavior and oxidative stress. Net: a real, mechanism-backed signal that has not cleanly replicated at scale, so tPBM is a promising adjunct to confirm, not an established antidepressant or a substitute for proven care.

Transcranial PBM significantly alleviated depression symptoms vs. sham across 11 RCTs (SMD -0.55); sleep outcomes were NOT significantly improved in the same meta-analysis. Requires skull-contact NIR device — not consumer panels.

In experimental autoimmune encephalomyelitis (the standard MS model), PBM consistently reduces clinical disease score, delays onset, lowers CNS nitric oxide, attenuates demyelination and boosts oligodendrocyte precursors (Gonçalves 2016, Muili 2012, Duarte 2018) — a robust disease-modifying signal in animals. In people, the controlled human evidence is narrower: a double-blind crossover RCT (Rouhani 2024) found high-dose PBMT improved muscle force recovery in pwMS, though fatigue didn't reliably change. So the honest claim is disease-modifying in animals, symptom-supportive (muscle performance) in early human data — not proven to alter MS itself in humans.

Parkinson's is the clearest case of PBM's preclinical-vs-clinical gap. In MPTP mouse and macaque models, NIR light (670/810 nm) repeatedly rescued dopaminergic neurons in the substantia nigra and improved motor behavior — even in a primate model the authors framed as a template for clinical translation. Yet the human RCTs to date show no statistically significant effect on most clinical outcomes vs placebo (Bullock-Saxton 2021, Santos 2019). So the mechanism is robust and genuinely exciting, but human efficacy is unproven — an honest 'not yet,' not a dismissal.

Preclinical TBI work is strong and consistent — transcranial 810 nm light preserved mitochondrial membrane potential, cut apoptosis and reactive oxygen species, increased synaptic proteins and neuron survival, and improved neurological scores in rodent models (with a clear treatment-schedule dependence: 1-3 sessions helped, 14 did not). In humans, however, the controlled signal is weaker: in moderate TBI, PBM showed only statistically non-significant improvement over sham (Longo 2020). So the honest read is a compelling mechanism awaiting convincing human confirmation — direction mixed.

Across ~7 human reports (case series and a retrospective cohort), photobiomodulation reduced pain and mucosal symptoms in oral chronic graft-versus-host disease, often refractory to topical steroids. Finfter 2021 found at least 50% pain reduction in 77% of 56 sessions (mean pain 5.2 to 1.4), and Epstein's series documented improved oral sensitivity, dryness, and even fibrotic changes. The consistency across independent groups is encouraging for this hard-to-manage, non-immunosuppressive adjunct, but the absence of randomized trials keeps the grade at limited - confirmatory controlled studies are explicitly called for.

Across several small human trials, light therapy to the sinuses has produced inconsistent results: an 830 nm LLLT sham-controlled trial improved total symptom scores (Cohen's d ≈ 0.69), and mixed UV/visible rhinophototherapy helped chronic rhinosinusitis with nasal polyps, yet a double-blind UV/VIS trial in CRS without polyps found no benefit over placebo. The honest read is encouraging-but-heterogeneous, and several 'positive' studies used ultraviolet/visible rhinophototherapy rather than pure red/NIR PBM. Treat sinus PBM as an adjunct to standard CRS management, not a replacement.

Across small case series and one 9-patient single-arm trial (Wade 2021), LED phototherapy - blue (~447-480 nm) plus red (650 nm) light and biophotonic fluorescent light energy (FLE/Kleresca) - reduced papulopustular inflammation, flushing and erythema in rosacea with good tolerability. The evidence is early: mostly uncontrolled case reports/series without blinding, so the true effect size is uncertain. A reasonable adjunct to standard anti-inflammatory rosacea therapy, not a replacement.

Catheter-delivered intravascular light therapy during coronary stenting has, in single-arm human series, produced low restenosis rates (~14.7% in De Scheerder 2000, n=68) and appeared feasible and safe. However, the lone randomized trial (Derkacz 2010, 808 nm, n=101) found the restenosis-rate difference non-significant (15.0% vs 32.4%) even while minimal lumen diameter and late lumen loss improved significantly. So the signal is real but unproven on hard endpoints. Note this is intravascular delivery during PCI — it has nothing to do with transdermal or full-body red-light devices.

Five small human studies indicate low-level diode laser (typically 685/830 nm) can improve denture stomatitis, including fungicidal effects on Candida and superior mucosal healing versus conventional care (Marei 1997; Maver-Biscanin 2004/2005). The signal is real but modest, and not uniformly superior: Maciel 2015 found topical miconazole outperformed photodynamic therapy plus low-power laser (80% vs 40% cure). Reasonable as an adjunct - especially where antifungal tolerance or compliance is an issue - rather than a first-line replacement for antifungals and denture hygiene.

Four human case reports/series report that infrared and near-infrared light - water-filtered IR-A plus visible (580-1400 nm), whole-body IR-A (800-1400 nm), and 940 nm NIR - improved skin sclerosis, cosmesis and Raynaud symptoms in cutaneous/linear/limited-systemic scleroderma, including 7 of 10 responders in von Felbert 2011 who had failed conventional therapy. All are uncontrolled, so this is a promising but unproven signal in a hard-to-treat fibrosing disease. PBM/IR is an adjunct to rheumatologic care, not a replacement.

Hearing loss shows a classic preclinical-clinical gap. Rat studies are encouraging - Lee 2016 (808 nm) and Rhee 2013 (830 nm) both improved hearing thresholds and hair-cell counts - but the two human RCTs here are negative: Williams 2024 (850 nm crossover) found no protection against noise-induced temporary threshold shift, and Goodman 2013 found no audiometric benefit. The honest read: a real, reproducible animal mechanism that has not translated to humans yet, likely due to inadequate light delivery to the cochlea; not a recommended therapy for hearing loss today.

In rodent models, red-to-NIR phototherapy produces rapid, robust analgesia: multisource 890 nm LED cut formalin/acetic-acid nocifensive behavior, and 810 nm PBM to the dorsal root ganglion more than tripled paw pain thresholds (de Sousa 2018). Human experimental-pain trials back this up — pulsed 830 nm raised Aδ- and C-fiber thresholds versus sham, and blue light reduced spontaneous pain and hyperalgesia. The mechanism is well-mapped and the early human signal is encouraging; PBM is a reasonable analgesic adjunct, with clinical (vs experimental) acute-pain trials still the gap to close.

Onychomycosis is a cautionary tale in honest grading. Open-label and retrospective studies look good — 89% clinical improvement with a triple-wavelength (650/810/915 nm) laser plus abrasion (Aukstikalnyte 2022), reduced severity and positive-culture rates with Nd:YAG 1064 nm (Hees 2014), and 46.6% excellent improvement retrospectively (Kiran 2024). But the most rigorous test, a prospective double-blind randomized controlled trial, concluded that 1064 nm Nd:YAG laser was not effective for onychomycosis (Sabbah 2019). Importantly, much of this is photothermal Nd:YAG laser, not classic photobiomodulation. Net: encouraging uncontrolled data undercut by a negative RCT — direction mixed, grade limited.

Psoriasis responds to visible-light therapy, though the strongest controlled data are for blue light rather than classic red/NIR PBM. Randomized trials show high-dose blue (420 nm) and red (630 nm) both improved plaques, with blue continuing to reduce erythema (Kleinpenning 2012), and 453 nm blue light significantly improved the Local Psoriasis Severity Index versus untreated control plaques (Pfaff 2015). A red+NIR (633+830 nm) LED case series reported 60-100% clearance with high satisfaction (Ablon 2010), and a red/NIR-emitting fabric helped some patients (Pixley 2023). Honest read: real benefit for localized plaques, much of it blue-light-driven; red/NIR data are promising but smaller and partly uncontrolled.

Several human studies in older adults with mild cognitive impairment show transcranial PBM improving global cognition, working memory and regional cerebral blood flow (Lee 2025 controlled, Baik 2021, Chun 2026), with effects tracked by fNIRS and SPECT. The signal across studies is encouraging for a population with few good options. Two honest caveats: many studies are single-arm or small, and a recurring theme is that a meaningful fraction of people are non-responders — so individual benefit is variable and not guaranteed.

Several small human RCTs support PBM after total knee arthroplasty. Bahrami 2022 (n=45, 804 nm) showed greater range of motion through 3 months, Chia 2025 (n=30) found less postoperative swelling and longer walking distance, and Huang 2022 (sham-controlled, n=82, 808 nm laser acupuncture) reduced pain and morphine use in the first 72 hours. Consistent early-recovery benefits make PBM a reasonable adjunct for post-TKA rehabilitation, though trials are small, sometimes unblinded, and parameters are inconsistently reported.

Small human studies suggest transcranial infrared laser (1064 nm) to the prefrontal cortex can raise oxidized cytochrome c oxidase and cerebral oxygenation and improve cognitive flexibility/impulsivity in older euthymic bipolar patients (O'Donnell 2021, small sham-controlled crossover), and a four-patient case series reported reduced anhedonia. The mechanistic rationale — targeting prefrontal mitochondrial hypometabolism — is strong, but the clinical evidence is preliminary (tiny samples, mostly single-arm). Position tPBM as an experimental adjunct for cognitive symptoms, never a replacement for mood stabilizers, and with caution given mania-activation theory.

Small pediatric RCTs of low-level laser applied to acupuncture points report better asthma control, improved spirometry, and lower exhaled oxidative-stress markers versus sham (Dabbous 2017: 91.7% vs 25% improved control). This sits on a large, mechanistically rich animal literature where 660-780 nm LLLT reduces bronchial hyperresponsiveness, Th2 cytokines, and eosinophilia. The human signal is encouraging but comes mostly via laser acupuncture in children, so it is a limited-to-moderate adjunct case — and a hard safety line: PBM must never replace inhaled controllers or rescue therapy in asthma.

Two randomized sham-controlled trials reported real improvements with PBM in ASD: Leisman 2018 cut Aberrant Behavior Checklist irritability (adjusted mean difference −15.17 vs placebo) with red-laser application to the skull/temporal areas, and Fradkin 2024 improved CARS scores (between-group difference 7.23) with 850 nm transcranial PBM in young children. Open-label and retrospective transcranial studies echo benefits on social responsiveness and rigidity. This is a genuinely promising, mechanism-plausible signal for a condition with few options — but samples are small and it must be framed as an adjunct under clinical supervision, not a cure.

A 16-patient single-arm pilot (Gerkowicz 2019) using 630 nm superluminescent LEDs as an adjuvant in frontal fibrosing alopecia and lichen planopilaris significantly reduced disease-activity scores (LPPAI p=0.012, FFASS p=0.017) and increased thick-hair counts over 10 weeks, well tolerated. This is a single uncontrolled pilot plus small case reports; a systematic review (Jafari 2024) notes most LLLT alopecia data are in androgenetic, not cicatricial, alopecia. Encouraging as an adjuvant to standard immunomodulatory therapy, not a stand-alone cure for scarring alopecia.

Amblyopia is classically treatable only in childhood, so the signal here is interesting: Ivandic (2012) reported visual-acuity gains in ~90% of treated eyes (>=3 lines in over half) in 178 mostly adult patients with 780 nm laser, and a 2025 pediatric randomized study found low-level red light accelerated acuity gains while slowing axial elongation in myopic amblyopia (Li 2025). A 2026 case report adds an anecdotal adult signal. Promising and mechanism-plausible, but built on one older RCT/comparison, a small pediatric trial and case-level data.

Bone repair has a very large preclinical PBM literature (~187 animal studies) showing accelerated healing: Magri 2015 and Nascimento 2015 (rat, 780-808 nm) found more new bone, higher alkaline phosphatase, and healing in diabetic animals approaching that of healthy controls, and systematic reviews converge on roughly 5 J/cm2 at low irradiance as an effective dose window. Human data remain sparse (only ~3 studies here), so this is a strong, well-mapped mechanism with translation still in early stages - promising as an adjunct to fracture/graft healing to be confirmed in human trials, not yet a proven clinical standard.

For chemotherapy-induced alopecia the signal is genuine but mixed. In a rat model, a 655 nm laser comb significantly accelerated regrowth without compromising chemotherapy efficacy (Wikramanayake 2013). Two human RCTs in breast-cancer patients consistently improved quality-of-life and global-health scores with PBM (Lodewijckx 2023, 678 nm; Claes 2025), yet neither showed a statistically significant difference in scalp coverage or hair thickness versus control. Honest read: encouraging animal data and reproducible QoL benefit, but human hair-regrowth efficacy is not yet demonstrated, and trials are small.

Four human studies address PBM/light for split-thickness skin-graft donor sites: a self- and sham-controlled RCT (Monstrey 2002, n=20, polarized 400-2000 nm light) showed significantly better donor-site healing across nearly all variables, while a controlled case series (Carboni 2021, 660 nm) found no change in re-epithelialization or wound area but a real reduction in pain. Case reports add that wIRA rescued infected donor sites. The evidence is encouraging but mixed across endpoints and small - a reasonable adjunct for donor-site comfort and possibly healing, not a guaranteed accelerator of closure.

Human data on PBM and hypertension are genuinely mixed. An older single-arm study reported an 80% effectiveness rate (Umeda 1990, 830 nm), and a 635 nm course reduced daytime systolic/diastolic pressure by roughly 7% in patients with hypertension plus hyperuricemia (Kovalenko 2018); a large observational series found only minimal, transient BP reductions (Fatu 2025, n=268). But a randomized trial of intravascular laser (Pacheco 2024, 660 nm ILIB) found no significant effect on systolic or diastolic pressure. Net: an honest signal toward modest, possibly transient effects, not reliable antihypertensive efficacy — and several positive studies used systemic/intravascular delivery rather than a skin device.

Human infertility data for PBM are suggestive but not conclusive: a controlled study (Tsai 2020, 633 nm He-Ne before frozen-embryo transfer) found higher clinical-pregnancy (37.9% vs 35.5%), implantation and live-birth rates, but none reached statistical significance; retrospective (Ohshiro 2012) and case-series (Phypers 2024) reports describe pregnancies in difficult cases, and an old series (Hasan 1989) noted increased sperm counts in oligospermia. The direction is encouraging and mechanism-plausible (improved endometrial microcirculation, mitochondrial support of gametes), but controlled evidence is underpowered and non-significant. Strictly an adjunct to confirm - never a substitute for reproductive-medicine care.

Most osteoporosis evidence is preclinical (20 animal studies), with a handful of human trials. High-intensity laser combined with exercise modestly increased lumbar BMD beyond exercise alone (Alayat 2018, sham RCT, n=100), and a small spinal-cord-injury single-arm study (Mohammadzadeh 2024) saw site-specific BMD and vitamin-D gains - but laser alone was generally not enough. The honest read: a real osteogenic mechanism in animals and a modest human adjunct-to-exercise signal, not a standalone osteoporosis treatment; weight-bearing exercise and pharmacotherapy remain primary.

Multiple human studies converge on a real, measurable hemodynamic effect: a single transcranial PBM session increases oxygenated hemoglobin and decreases deoxygenated hemoglobin in both hemispheres (Tian 2016, 1064 nm), and transcranial LED therapy raised middle-cerebral and basilar artery flow velocities by 17-30% with lower pulsatility in older women (Salgado 2015). This is one of the better-documented mechanistic effects of brain PBM. The honest framing: these are short-term, mostly uncontrolled physiologic measurements — they establish the mechanism, not a clinical outcome.

One small randomized trial (He 2026, n=30, 590 nm and 590/630 nm LED) and two single-arm trials (Choi 2013 n=28; Sonbol 2020 n=30) showed LED phototherapy significantly reduced Sensitive Scale-10 scores and irritation markers (erythema, TEWL), with benefit persisting about 2 months. The randomized evidence is thin (one small RCT) but the direction is consistent and mechanism-plausible. A well-tolerated adjunct for sensitive-skin syndrome.

RP has no approved therapy, which makes the PBM signal worth attention: a small comparison study recovered a mean 5.4 ETDRS letters at 8 weeks (Casson 2022), and several case reports/series describe improved acuity, visual fields and night vision, including durable gains over years with retreatment after relapse (Ivandic 2014; Koev 2015; Luque-Mialdea 2023). Encouraging and mechanism-plausible, but the evidence is dominated by case reports/series with small numbers and high variance — hope-worthy, not yet proven.

Several human studies suggest PBM can reduce centre-involving diabetic macular edema without injections: a Phase II program (Shen 2020) paired mechanistic mouse/cell work with a 670 nm human trial showing improved mitochondrial function and reduced retinal vascular leakage; Chen (2022) saw BCVA rise (71.8 to 79.5) and retinal thickness fall over 12 months with no complications; and multiwavelength PBM (590/660/850 nm) reduced central retinal thickness and resolved intraretinal fluid in select patients (Kaymak 2023). All seven human studies point favorably, but most are single-arm/retrospective, so a non-invasive alternative to repeated injections is plausible, not proven.

Several reports suggest PBM can trigger hair regrowth in alopecia areata: a 660 nm laser used as monotherapy produced significant regrowth within days in a case report (Palma 2023), an incidental case showed terminal regrowth under a green/red-IR-emitting smartwatch (Duncan & Tziotzios 2025), and a self-controlled randomized study with infrared (Super Lizer) achieved regrowth in 7/15 irradiated areas versus 0/15 non-irradiated (Yamazaki 2003); a mouse model with a 655 nm laser comb corroborates the effect. The direction is encouraging and mechanism-consistent, but the human data are small and uncontrolled-to-semi-controlled, and AA's natural relapsing-remitting course is a real confounder.

The leprosy evidence cuts both ways. An early RCT (Barreto 2010, 660 nm) found no significant benefit of LLLT for wound healing, but more recent RCTs combining PBM with physiotherapy report reduced neuropathic pain and better functional capacity (SALSA scale) versus physiotherapy alone. So the honest claim is target-dependent: PBM does not appear to heal leprosy ulcers, yet may help the neuropathic pain and disability that follow nerve damage. All trials are small (25-30 patients).

Three human case reports/series (Schindl, 1997-2000) using 632.8 nm He-Ne laser at about 30 J/cm2, three times weekly, achieved complete closure of chronic post-radiotherapy skin ulcers within 5-8 weeks, with no recurrence over 18-36 months in survivors. These are uncontrolled case reports, not RCTs, so causation versus natural healing cannot be cleanly separated - an encouraging signal that warrants controlled trials. PBM here is a localized-laser adjunct to standard wound care, not a replacement.

Three human trials show near-infrared light (650-940 nm) to the lower legs/acupoints significantly reduces restless-legs symptoms versus control over a 4-week course (Mohammadi 2018; Mitchell 2011 ×2), with two devices/wavelengths working comparably. Benefit was clear during treatment but tended to fade after stopping in the hemodialysis cohort. It is a low-risk, drug-sparing adjunct worth trying, with the caveat that durability and long-term data are limited.

Tinnitus has one of the bigger PBM literatures here (12 human RCTs, 9 non-RCTs, a case series), but the results genuinely conflict. Some sham-controlled trials report meaningful VAS improvements (e.g., Demirkol 2017 with Nd:YAG 1064 nm), while well-designed double-blind trials (Mirz 1999, 830 nm transmeatal) and a recent RCT (Choi 2024, 830 nm) found no significant clinical benefit over placebo despite encouraging animal data. The signal is real enough to keep studying, but PBM is not a reliable tinnitus cure and should be framed as an experimental adjunct.

A large body of human experience supports PBM for herpes-zoster pain, especially postherpetic neuralgia. A striking case documented a 15-year, treatment-resistant PHN dropping from 8/10 to 0/10 pain over 8 weeks of laser therapy (Knapp 2013); a 29-year retrospective series treated 123 PHN patients with 830 nm (Sasaki 2010); and a single-arm study reported final pain scores of 0 in 11 of 15 patients with 650 nm (Mukhtar 2020). The direction is consistently toward pain relief, but most studies are uncontrolled and an early crossover study itself noted a placebo effect — so the honest grade is limited despite the volume.

A small human non-RCT (Hosseini 2023, 660 nm) in traumatic anosmia/hyposmia found that LLLT increased activation in olfactory-related cortex and reshaped olfactory-network connectivity, and a mouse stroke model (Shalaby 2023, 808 nm) showed PBM to the olfactory bulb accelerated smell recovery by suppressing inflammatory cytokines and boosting glial/vascular repair factors. The convergence of a human neuroimaging signal with an animal recovery mechanism is encouraging for a hard-to-treat deficit. But the human study is small and uncontrolled by randomization, so this is an early lead.

Brief low-intensity laser irradiation of the limbus reduced intraocular pressure in human eyes — by ~25.7% in ocular-hypertensive eyes and ~17.1% in normotensive eyes in a 211-eye case series (Ivandic 2009, p<0.001), with a smaller controlled study echoing an IOP drop (Dimitrova 2019) and a rat study showing red light protects the retina from a raised-IOP insult (Del Olmo-Aguado 2016). A real directional signal for IOP lowering, but the human work is uncontrolled/older, one study used a heat lamp (thermal confound), and the original framing was diagnostic rather than therapeutic.

Diabetic dermopathy has limited but encouraging human data. In a placebo-controlled split-body pilot (12 type-2 diabetics), the 632 nm LLLT-treated side showed significant improvement in lesion diameter and in knee/ankle skin blood flow versus the placebo side (Abdelhalim 2020), and a case report described normalized skin color by day 21 alongside improved diabetic neuropathy with 830 nm (Hazari 2017). The within-patient control design is a strength for such a small study; the evidence is limited but points clearly toward benefit via improved microcirculation and healing.

For childbirth-related analgesia the human evidence is mixed-to-negative: a triple-blind RCT (Alvarenga 2016) found LLLT gave no benefit for post-episiotomy perineal pain with the parameters tested, while older human work (Laakso 1994) showed PBM raised ACTH and beta-endorphin, and animal studies (de Oliveira 2021, starred) demonstrate dose-dependent antinociception via peripheral opioid and endothelin-B receptors. So the mechanism is real but a key human obstetric trial was null - likely a dosing/protocol problem rather than absence of effect. Limited overall; PBM is at most an adjunct, and optimal obstetric analgesia protocols are unproven.

For lichen planopilaris, a scarring alopecia with few good options, two case series report meaningful benefit: a significant mean drop of 0.87 in the LPP Activity Index after six months of 630 nm light (Fonda-Pascual 2017) and dramatic responses with reduced inflammation, symptom resolution, and hair regrowth in four patients (Randolph 2020). However, an ex-vivo transcriptomic study found no significant differentially expressed genes in the LLLT arm before versus after treatment (Yildiz-Altay 2025), leaving the mechanism unconfirmed. Honest read: clinically promising in small uncontrolled series, but the molecular evidence is so far neutral — a mixed, limited picture.

In a randomized study of vocal-loading-induced fatigue, red-wavelength LLLT (628 nm) significantly normalized phonation threshold pressure and related measures versus infrared, heat, and control, and a single-arm study of 41 teachers found immediate acoustic and respiratory gains after one PBM session (largest in those with severe fatigue). The evidence is early — small samples, mostly single-session, partly confounded by surface heating — but consistently points toward benefit. PBM looks like a promising rapid adjunct for professional voice users, not a stand-alone voice therapy.

In community-acquired pneumonia, a 940 nm LED vest added to standard care (a small RCT, n=30) improved pulmonary recovery and SpO2 (88→98%) and shortened hospital stay (9.3 vs 7.3 days; p=0.0015), echoed by an earlier non-randomized study from the same group. The signal is encouraging and the delivery (a thoracic LED vest) is practical, but the evidence is one small RCT plus a non-RCT. PBM here is a plausible adjunct to confirm — strictly alongside antibiotics and physiotherapy, never instead of them.

In experimentally induced rat tibial osteomyelitis, 808 nm laser cut infection levels dose-dependently (up to ~93% reduction with debridement plus light), and a small human series in jaw osteomyelitis (n=8, 635 nm) reported better clinical outcomes and significantly less pain than controls after surgery. The combined picture is encouraging for PBM as a post-surgical, anti-infective adjunct. But the human data are tiny and non-randomized, so this is a promising lead rather than proof.

Small pediatric RCTs suggest photobiomodulation (often over masticatory muscles or acupoints) can ease sleep-bruxism-associated symptoms — Salgueiro 2020 (n=76) significantly reduced headache frequency, comparable to occlusal splints, and Kobayashi 2022 examined EMG/dopamine effects with infrared LED. The findings are encouraging and PBM sidesteps the cooperation problems of splints in children, but the trials are small and outcomes heterogeneous. Reasonable as an adjunct to confirm, alongside standard bruxism/dental management.

The cerebral-palsy evidence is largely observational but consistent: Asagai's series reported improved gross motor function in a subset of 73 children and suppressed myotonia in 19 of 20 patients, and a more recent small RCT (Abdelhalim 2023, 810 nm) showed power gains in quadriceps and dorsiflexors in children with spastic diplegia. PBM appears most useful as a pre-stretching/pre-training adjunct that lowers pain and muscle tone so functional therapy can do more. The evidence base is thin and mostly non-randomized, so confidence is limited but the direction is encouraging.

The concussion evidence is genuinely mixed. A detailed case report (Chao 2020) documented behavioral and neuroimaging improvement after 8 weeks of home transcranial PBM in a player with chronic post-concussion symptoms, and recent mouse studies show PBM improves cortical perfusion, oxygenation and brain waste-clearance after repeated concussion. But the controlled human test (Taylor 2023 RCT) found no benefit of transcranial PBM over placebo for persistent post-concussion symptoms. So mechanism and anecdote are encouraging while the best human evidence to date is null.

The signal here is genuinely mixed. Borshchenko (2022) reported a 14% rise in MRI disc-signal intensity after 1560 nm Er-fiber laser irradiation of lumbar discs (p<0.001), suggesting a regenerative/reshaping effect on cartilage, while Taradaj's (2018) placebo-controlled trial found laser improved patients but no better than placebo. So there is a provocative imaging signal for disc regeneration, but clinical superiority over sham is unconfirmed.

Two human case reports describe symptomatic relief of cancer-related dysphagia with PBM: water-filtered IR-A (Hoffmann 2017) reduced viscous secretions and dramatically improved sleep and quality of life within days, and 980 nm PBM (El Mobadder 2019) improved swallowing in hormonal-therapy-related dysphagia. These are single-patient anecdotes in palliative/supportive-care contexts - genuinely encouraging for symptom relief but not generalizable evidence. PBM is a supportive adjunct under oncology/supportive-care guidance, not a treatment for the underlying disease.

Two human reports (Epstein 2016 case series of 3; de Bataille 2017 case report) describe rapid resolution of persistent, symptomatic oral mucosal necrosis - including post-radiation ulceration - after adding photobiomodulation, with notable pain relief (one patient cut analgesic use threefold). For a difficult oncologic complication with few options this is an encouraging adjunct, but the evidence is anecdotal and uncontrolled.

Two human trials suggest LLLT helps cubital tunnel syndrome in the near term but not durably. Yağcı 2024 (sham-controlled RCT, n=64) found laser superior to placebo at 3 weeks but equivalent by 3 months, and a randomized comparison (Wieczorek 2025) showed electrophysical modalities including LLLT improved nerve-conduction and ultrasound measures comparably to manual neurodynamic therapy. So LLLT looks like a reasonable short-term adjunct for symptom relief, with benefit that converges with controls over time.

Two randomized, sham-controlled trials of NIR/red PBM for provoked vestibulodynia both moved pain in the right direction: Lev-Sagie 2017 found 78% of LLLT (820 nm) patients improved vs 44% on sham (P=0.042), and Antonio 2025 found greater vulvar-pain reduction with real PBM than sham. The honest caveat is that Antonio's patients did not perceive real PBM as clearly better than sham, and psychological and sexual-function outcomes didn't move. So PBM looks like a reasonable, low-risk option for vulvar pain with a genuine but modest effect.

Two small human reports suggest possible benefit in Meniere's disease. Teggi 2008 (randomized vs betahistine, ~10-20 patients) found PBM reduced the number and duration of vertigo spells - though more slowly than betahistine, with no audiometric improvement and no placebo arm - and a 2026 case report described vertigo resolution with combined electroacupuncture and LLLT. This is a weak, preliminary signal for vertigo control only; PBM is at most an adjunct to test, not a substitute for established Meniere's management.

Two small human studies point in a hopeful direction: transcranial NIR PBM (823 nm) improved sexual function as a secondary outcome of a depression trial, and intra-/extra-cavitary PBM (440 + 660 nm) sharply reduced vaginal pain and raised sexual-function scores in breast-cancer survivors on hormone therapy. The mechanism plausibly differs by site — central (brain/desire) versus local (tissue/pain) — and a mouse study reinforces a central dopaminergic pathway for desire. Encouraging but preliminary: samples are 20-32 people, one is a non-randomized secondary analysis, so this is a signal to pursue, not a settled treatment.

Two small human studies point in a positive direction for oral leukoplakia. Ribeiro's RCT (n=18) used 660 nm laser to reduce pain after cryosurgical removal of leukoplakia, and Jagtap's 4-case series reported lesion-area shrinkage (437 to 223 mm2 after at least 10 treatments). One study is an analgesic adjunct to a destructive procedure, the other suggests direct lesion regression - both encouraging but preliminary. Given leukoplakia's premalignant potential, PBM should sit alongside, not replace, surveillance and definitive management.

Two small human studies suggest that pre-treating a tooth with low-level laser before cavity preparation reduces procedural pain. Femiano's sham-controlled trial (24 subjects, 88 teeth) found roughly 42% pain reduction in the laser group versus 16% in controls (p<0.0001), and Tanboga's non-randomized pediatric study reported lower VAS scores (median 1 vs 3, p<0.01). Encouraging and mechanistically reasonable for analgesia, but the trials are small with under-reported parameters, so treat this as a promising adjunct to confirm rather than a substitute for local anesthesia where indicated.

A 12-subject single-arm trial (Dudelzak 2009) found a 980 nm diode laser at high fluences (22-147 J/cm2) effectively treated facial telangiectasias without complications. Important caveat: at these energies the mechanism is selective photothermal coagulation of vessels - fundamentally different from low-level photobiomodulation - so this does not support red-light/NIR PBM (or full-body beds) for telangiectasia. Vascular laser treatment is a procedural dermatology intervention requiring a trained operator.

A 48-adult single-arm study of transcranial PBM (1064 nm) in ADHD reported significant working-memory and attention gains with sizable effect sizes (Cohen's d 0.84-1.26), peaking 2-3 weeks post-intervention, and a rat ADHD model showed PBM reduced hyperactivity while increasing prefrontal connectivity and dampening neuroinflammation. The convergence of a strong human signal with a mechanistic animal model is exciting for a condition where non-drug options are wanted. The catch: the human study had no control arm, so expectation and practice effects can't be separated yet.

A double-blind, placebo-controlled trial in 60 men found that red (650 nm) and infrared (820 nm) LLLT significantly reduced chronic groin/scrotal pain after varicocelectomy and increased sexual satisfaction over a 12-week follow-up. Post-surgical orchialgia is stubborn and under-served, so a positive sham-controlled result is genuinely encouraging. As a single trial, it should be confirmed independently before being treated as standard care.

A randomized, double-blind, placebo-controlled trial (Zhevago & Samoilova 2006, n=62) found transcutaneous polychromatic visible+infrared light (480-3400 nm, 12 J/cm2) dramatically reduced circulating pro-inflammatory cytokines in people with elevated baselines - TNF-alpha, IL-6 and IFN-gamma fell roughly 34x, 12x and 1.5x at 30 minutes - with a mouse study (Fukuda 2013, 780 nm) echoing reduced TNF-alpha/IFN-gamma. The human signal is striking but rests on a single RCT, so it is limited pending replication. Supports PBM as a systemic immunomodulatory adjunct, not a replacement for treating the underlying driver of inflammation.

A sham-controlled RCT (Carvalho 2010, n=28) found infrared 830 nm LLLT after inguinal-hernia surgery (applied 24 h post-op then days 3, 5, 7) significantly improved Vancouver Scar Scale scores, reduced scar thickness, increased malleability and roughly halved pain versus control. Promising and mechanism-consistent, but a single small trial - replication needed. PBM is a post-surgical adjunct, not a substitute for surgical technique.

A single case report (Campos 2021) describes antimicrobial photodynamic therapy plus PBM after incision and drainage of a perianal abscess, with no signs of infection or inflammation by day 5 and no fistula or recurrence at 3 months. This is one anecdote combining two light modalities, so attribution to PBM specifically is not possible. An encouraging hypothesis for adjunctive post-surgical care, not evidence of efficacy; standard surgical management remains primary.

A single-subject A-B-A case report used monochromatic infrared light (890 nm, Anodyne system) in a man with acromegaly-related sensorimotor polyneuropathy and documented behavioral/sensory improvement that appeared only during the intervention phases, alongside laser-Doppler-measured changes in red-blood-cell flux. The A-B-A design strengthens causal inference for an n-of-1, which is meaningful. But it remains one patient — a hypothesis-generating signal, not generalizable evidence.

A small randomized controlled trial (Foo 2020, n=14) found that 808 nm PBM (4 J/cm2, 50 mW, daily x10) after Oberlin-procedure neurotization for brachial plexus injury produced more signs of reinnervation and significantly higher mean muscle power by 3 months, with no adverse effects. This is one small RCT - promising and mechanism-consistent, but underpowered and in need of replication. PBM is a surgical adjunct to support nerve regeneration, not a substitute for neurosurgical repair.

After allogeneic scleral grafting for contracted sockets, 650 nm LLLT significantly accelerated conjunctival vascularization (p=0.003) and reduced fornix contraction versus controls in a 39-patient randomized, double-blind study (Huang 2023). A clean directional result for a reconstructive challenge — limited by small size and some methodological ambiguity in the report.

An early single-arm series of 90 patients reported a 94.4% effective rate for radicular cervical spondylosis treated with laser therapy combined with Traditional Chinese Medicine (Li 1992). The number is eye-catching, but with no control group and laser bundled with TCM, it cannot isolate a PBM effect — this is a historical signal worth testing properly, not evidence of efficacy.

Combined with hydroxyapatite orbital implantation, 650 nm LLLT promoted conjunctival graft survival, incision healing and early vascularization in a 10-patient case series, with a companion rabbit model probing mechanism (Xu 2021). A reasonable wound-healing signal for a niche surgical problem, but the human evidence is a small uncontrolled series.

Direct evidence that photobiomodulation prevents dental caries is weak. One human RCT (Nemeth 2019) found that irradiating major salivary glands shifted caries-risk markers favorably - lower Streptococcus mutans and Lactobacillus counts and higher salivary buffering (p<0.05) - while a rat study (Mueller 2007) showed laser alone added nothing to fluoride. The honest read is a plausible salivary/antimicrobial mechanism with one supportive human trial, not a caries-prevention therapy; fluoride and standard preventive care remain the foundation and PBM at most an adjunct to confirm.

Evidence for PBM in oral cicatricial pemphigoid is a single case report (Oliveira 2009): 660 nm laser phototherapy added to systemic steroids was associated with better lesion control, oral health, and quality of life. This is anecdotal - one patient, no control - so it can only be framed as a plausible, low-risk adjunct to standard immunosuppression in this rare autoimmune blistering disease, never a replacement for it.

Evidence is a single multicenter RCT (Kiricsi 2022, n=30): adding mixed ultraviolet-visible (280-650 nm) phototherapy to intranasal steroids after endoscopic sinus surgery significantly reduced nasal-polyp recurrence, size, and obstruction. A genuinely encouraging result - but note it uses immunomodulatory UV-visible light rather than classic red/NIR PBM, and one trial cannot establish the effect. Reasonable as an adjunct to surgery plus steroids, pending replication.

Evidence is a single small RCT (Liu 2014, n=21, 810 nm): low-level laser combined with eccentric exercise outperformed laser alone (and exercise comparators) on most outcomes, though pain relief between laser+exercise and laser alone was similar. This is consistent with PBM's role as an exercise-potentiating adjunct for tendinopathy, but with only one small trial here, it is a promising lead to confirm rather than established practice.

Evidence is a two-case series (Moreira 2004) in cerebral-palsy patients with traumatic lip ulceration, where 685 nm laser accelerated healing, reduced secondary contamination, and provided analgesia. This is consistent with PBM's well-documented soft-tissue wound-healing effects, but it is anecdotal - useful as a supportive adjunct for difficult-to-manage labial trauma, not an evidence-backed standalone therapy.

Evidence is limited to a single case series (Sindici 2017): 904 nm laser treated 19 oral lesions across 7 patients with dystrophic epidermolysis bullosa, with reported clinical benefit over follow-up. For a rare, blistering, exquisitely fragile-tissue disease with few good options, this is an encouraging, low-trauma adjunct worth formal study - but it remains anecdotal and is not a disease-modifying therapy.

Evidence is one case report (Leite 2020): 660 nm PBM supported healing of palatal necrotizing sialometaplasia, a rare, self-limiting but locally destructive benign lesion. PBM's regenerative wound-healing profile makes this a reasonable supportive adjunct, but with a single uncontrolled case - and a condition that often resolves on its own - this is anecdotal and hypothesis-generating only.

For treatment-resistant Demodex blepharitis, combined IPL + low-level red/blue light significantly improved symptom scores (12.0 to 7.8, p=0.003) with no adverse events in a 17-patient retrospective series (Farrant 2025), and an 808 nm PBM rat model showed reduced eyelid inflammation and improved tear volume/break-up time (Kim 2020). A reasonable, low-risk adjunct signal — but the human data are retrospective and bundled with IPL, so the PBM-specific contribution is not isolated.

Hidradenitis suppurativa has preliminary but interesting PBM support. A retrospective series of 16 patients treated with an 808 nm diode laser showed a significant drop in disease severity (median modified HS score 20 to 9 at six months) (Ozdemir & Tamer 2024), and in-vitro work on HS genetic cell models shows PBM reduces inflammatory IL1B expression and supports cell metabolism and migration (Zupin 2020; Ferri 2019). A note of honesty: much laser use in HS is photothermal follicle-targeting rather than classic photobiomodulation, so mechanism attribution is mixed. The direction is supportive; the human evidence is limited and uncontrolled.

In 26 eyes with chalazia unresponsive to prior pharmaceutical or surgical treatment, a single 15-minute LLLT session (with standard meds) resolved 46%, rising to 92% after a second session (Stonecipher & Potvin 2019). For lesions already failing conventional care, that is an encouraging, low-risk option — though it is a retrospective chart review with concurrent pharmacotherapy, so controlled confirmation is needed.

In 90 eyes of 45 Stargardt patients, a year of twice-daily 650 nm PBM improved best-corrected visual acuity (0.7 to 0.4, p<0.001), PERG amplitude and microperimetry (Scalinci 2022). For an inherited macular dystrophy with no approved treatment, a functional-improvement signal is meaningful — but it is a single-arm, uncontrolled study, so the result is promising rather than established.

In a 53-patient, 123-lesion single-arm trial, red LLLT (635 nm, 75 J/cm2) produced complete response in 91% of early-stage (low-grade) cutaneous leishmaniasis lesions at 10 months, while high-grade lesions did not respond. For a disfiguring infection with toxic standard treatments, that is a genuinely promising signal. But it is a single uncontrolled study, so spontaneous healing and selection can't be excluded — a controlled trial is the necessary next step.

In a 60-patient double-blind, placebo-controlled trial, both red (650 nm) and infrared (820 nm) LLLT significantly reduced chronic testicular pain at 6 and 12 weeks versus sham, and also improved sexual satisfaction. That is a clean, placebo-controlled result for a notoriously hard-to-treat condition. It is one trial, so confirmation in independent cohorts is the next step before calling it established.

In a 63-patient RCT, adding high-intensity laser therapy to spinal decompression significantly improved disability (ODI), lumbar flexion and straight-leg-raise versus decompression alone, though VAS pain (low back and radicular) did not reach significance (Chen 2018). Encouraging for function, honest about the pain endpoint — and note this is high-intensity laser, not classic low-level PBM, so the mechanism leans toward a biostimulatory/photothermal hybrid.

In a double-blind RCT of 66 adults with presbyopia and eye strain, short-term 650 nm repeated low-level red light significantly reduced asthenopic symptoms (CVS-Q) and improved accommodative amplitude versus sham (Song 2026). A clean, blinded positive result for an everyday complaint — limited by short duration and single-trial status, so durability and longer-term safety remain to be shown.

In a first-of-its-kind single-arm study, 16 women with frontal fibrosing alopecia received 630 nm LED therapy weekly for 10 weeks; total eyebrow hair count rose significantly, as did thick and mid-thick hairs, and the gain in total eyebrow hairs was still significant at 6-month follow-up (Gerkowicz 2021). Eyebrow loss in FFA is notoriously hard to treat, so a durable, well-tolerated regrowth signal is encouraging — but this is a small, uncontrolled study, so the grade stays limited.

In a retrospective series of 170 patients with corticosteroid-addiction (topical-steroid-withdrawal) dermatitis, 633 nm red light was associated with clinical relief in 85.9% — reduced lesion area and improved symptoms — with healing of the epidermis and reduced dermal inflammation on histology and no adverse events (Luan 2014). For a condition where stopping the offending steroid is itself the therapy, the lack of a control group is a serious limitation: improvement over time is expected. The signal is encouraging and the mechanism plausible, but this is uncontrolled evidence.

In a sham-controlled crossover trial of 28 healthy adults, linear-polarized near-infrared irradiation of the stellate ganglion significantly lowered the perceived dyspnea of resistive-load breathing across multiple loads (p ≈ .005-.009). It is a clever, mechanism-plausible proof-of-concept borrowing from pain-management practice, but it is a single small study in healthy volunteers with experimentally induced (not clinical) dyspnea. Worth following up in real respiratory disease; for now an experimental adjunct only.

In a single non-randomized controlled study, photobiomodulation was associated with good or satisfactory clinical improvement in 36 of 37 patients versus 6 of 25 controls (Maksimovich 2019) — a striking effect size for vascular parkinsonism, where options are limited. But without randomization, blinding, or replication, this is hypothesis-generating: encouraging enough to warrant controlled trials, not enough to claim efficacy.

In a treatment-refractory Kleine-Levin syndrome patient, intranasal red-light PBM combined with methylene blue was followed by remission of hypersomnia and cognitive/behavioral symptoms, with no relapse over 2 years. For an orphan disorder with no reliable treatment, that is a notable observation worth pursuing. But it is a single case in which PBM was co-administered with methylene blue, so the light's independent contribution cannot be isolated — purely hypothesis-generating.

In an 85-patient sham-controlled RCT, intra-oral 660 nm PBM to the tongue dorsum significantly reduced hypogeusia, ageusia and parageusia and prevented lingual papillae atrophy across the neutropenic and engraftment phases of hematopoietic cell transplant (Ferreira 2024). For a side effect with no well-established remedy, that is a meaningfully positive result — still a single trial, so replication would cement it.

In one case report, a patient with pemphigus vegetans showed rapid improvement of cerebriform plaques when treated with low-dose systemic corticosteroid plus high-fluence 640 nm visible red light (Wang 2020). Because PBM was combined with corticosteroid, its independent contribution cannot be isolated. It is a hopeful anecdote in a difficult autoimmune blistering disease, but single-case, adjunctive evidence only.

In one case report, a pregnant woman with acrodermatitis continua refractory even to the most potent topical steroid was successfully treated with low-level polarized polychromatic non-coherent light, with no side effects (Choi 2011). It is a genuinely encouraging anecdote in a hard-to-treat inflammatory dermatosis where steroid-sparing options matter, but it is a single case — hypothesis-generating, not evidence of efficacy.

In one published case, an elderly patient with atherosclerotic risk factors developed digital gangrene after a tourniquet procedure and recovered near-complete skin color and digit function within three months using a regimen that included adjuvant low-level light therapy (633 nm) alongside wound dressing and medication (Lueangarun & Tempark 2019). The PBM was one component of multimodal wound care, so its independent contribution cannot be isolated. This is a hopeful, mechanism-consistent anecdote — a single case report, not evidence of efficacy.

In post-stroke shoulder pain and hemiplegic hand edema, 830 nm laser therapy outperformed electrotherapy on pain, swelling, disability and independence in a 70-patient controlled clinical trial (Karabegovic 2009). It is a genuine human signal for a common, hard-to-treat complication, but it rests on one non-randomized comparison, so confirmation in blinded RCTs is the next step.

In six bichectomy patients (three treated, three controls), intra- and extra-oral 660 nm PBM reduced postoperative facial edema and pain (Bernal Rodriguez 2018). It fits PBM's well-established post-surgical recovery profile, but with n=6 and a descriptive design this is proof-of-concept, not evidence of efficacy.

Maksimovich's non-randomized controlled study reported good or satisfactory clinical improvement in nearly all treated Binswanger's disease and vascular-parkinsonism patients (~92%), with reduced dementia and motor impairment and recovered daily function over long follow-up. The effect size is dramatic, but the delivery is the crucial caveat: this used intracerebral transcatheter laser PBM — an invasive endovascular procedure — not transcranial or full-body light. It is a single uncontrolled-randomization study with a delivery route that cannot be assumed equivalent to non-invasive PBM.

One double-blind, placebo-controlled RCT (Toida 2003, n=20) found 830 nm low-level laser shortened the painful period of hand-foot-and-mouth stomatitis from 6.7 to 4.0 days (p<0.005), with 90% acceptability and no adverse events. A clean, mechanism-consistent result for symptom relief - but it is one small trial, so the finding is promising and worth replicating rather than established.

The evidence on photobiomodulation and tumor growth genuinely cuts both ways, which is exactly why caution is warranted. Some preclinical work shows inhibition — 465 nm blue light arrested papillary-thyroid-carcinoma proliferation (Zhao 2024) and 980 nm pulsed PBM delayed early tumor growth by reinvigorating CD8+ T-cell antitumor immunity (Wang 2026) — while Rhee (2016) found 650 nm LLLT increased anaplastic thyroid tumor size via TGF-beta1 and Akt/HIF-1alpha. A human case report describes PBM within a combined regimen for advanced NSCLC (Su & Wu 2022). Bottom line: direct irradiation of malignant or suspicious tissue can plausibly stimulate as well as suppress tumors depending on wavelength, dose and tumor type, so it should be treated as a relative contraindication pending human data.

The lone available trial of photobiomodulation after zygomatic (cheekbone) trauma (Bashiri 2021) did not demonstrate a clear benefit over control, despite a more upbeat author interpretation. With only one small study and no replication, there is no honest basis yet to recommend PBM specifically for zygomatic fracture recovery. The biological rationale - light-driven reductions in edema and inflammation that help other facial-bone injuries - remains plausible, so this is a 'not yet shown' rather than a 'doesn't work', and well-designed trials are needed.

The mechanistic case for PBM in corneal injury is strong: red light (625-635 nm) attenuated pressure-induced corneal endothelial damage and sustained mitochondrial activation (Nunez-Alvarez 2017), red light blunted blue-light toxicity in corneal epithelial cells (2019), and NIR (600-1200 nm) reduced opacity and neovascularization and improved regeneration in injured rat corneas (Uysal 2024). One human non-randomized controlled study reported ~42% faster healing after corneal foreign-body removal (Koev 2011). Encouraging and mechanism-rich, but the human evidence is a single study that is uncontrolled by modern standards.

The picture for atopic dermatitis is mixed. An older retrospective series reported 830 nm NIR reduced itch in 79% and skin eruption in 71% of patients (Morita 1993), and mouse studies show PBM can modulate the Th2 immune response and ameliorate AD-like lesions (Chen 2009; Kim 2016, 850 nm). But the most rigorous human test — a double-blind RCT of full-body blue light (415 vs 450 nm) — produced only modest reductions in itch and IL-31 and did not improve any objective measure of AD (Buhl 2023). Honest read: possible symptomatic (itch) benefit and good safety, but no convincing objective disease control yet, and delivery/wavelength clearly matter.

Two human studies test 904 nm PBM for capsular contracture after implant breast reconstruction. A phase II double-blind RCT (Azimi 2018, n=42) found no significant change in patient-reported outcomes or breast symmetry/shape, but significantly better clinician-reported breast softness and contracture grade (p<0.05); an earlier single-arm study (Johnson 2015) reported surgery avoided in 93.9% of grade III/IV cases with about 44% average stiffness improvement. The signal is mixed - objective/clinician measures favor PBM while subjective patient measures do not - so evidence is limited. A reasonable adjunct to explore, not a proven alternative to surgical revision.

Across ~15 rat/mouse studies, transcutaneous 650-660 nm PBM over the chest consistently reduces lung edema, neutrophil influx, MPO activity, ICAM-1, and TNF-α/IL-1β/IL-8 while raising IL-10 and antioxidant defenses (Mafra de Lima 2010; de Lima 2013; Costa Carvalho 2016). This is one of the more reproducible preclinical PBM stories — multiple labs, multiple injury models, consistent anti-inflammatory direction. It remains animal-only, so human use is a strongly motivated plausible extension to confirm, and PBM would be adjunctive to standard care.

Across dozens of in-vitro and ex-vivo studies, irradiating sperm with red/NIR light (notably 810 nm) consistently increases motility and restores mitochondrial energy in asthenozoospermic samples, with little or no DNA damage at appropriate doses — and a large pig field trial translated treated semen into better reproductive outcomes. This is one of PBM's most reproducible energetic effects, but it is a lab/IVF-handling intervention applied to collected semen, not light shone on a man's body. Wavelength and dose matter sharply: 810 nm helped while 635 nm reduced sperm energy in the same study.

Across several controlled canine studies, PBM added to TPLO (cranial cruciate surgery) recovery has mostly failed to beat sham: Chavez 2023 and Kennedy 2018 found no benefit (Kennedy even hinted at detriment or a beneficial control-light effect), while Rogatko 2017 (preoperative LLLT) showed better 8-week peak vertical force and Renwick 2018 showed improved ACOI gait but nothing else. The net is inconclusive — scattered positive endpoints against a backdrop of null results. PBM cannot be recommended as established TPLO care; further dose-optimized trials are needed.

In ex-vivo human blood and in-vitro work, low-level laser light has decreased whole-blood viscosity and erythrocyte aggregation while improving deformability (Elblbesy 2019, 635 nm), increased blood oxygen tension (PO2/SaO2 with 633 nm; Wasik 2007), and affected lipid-laden samples (Wang 2018, 405 nm) and stored red-cell stability (Mohammed 2024). These are real, measurable photophysical effects on blood properties — a credible mechanistic basis for claims about microcirculation and oxygenation. But they are test-tube findings; whether irradiating blood ex vivo translates to clinical benefit in a living person is a plausible extension to confirm, not established.

Three rat studies (Asencio-Arana group, 1988-1992) found 633 nm He-Ne laser at low doses (~1.9 J/cm2) nearly doubled anastomotic bursting strength by postoperative day 4 and improved epithelialization and neovascularization - but the effect vanished at higher doses (6.4 J/cm2), a classic PBM biphasic response. This is consistent preclinical evidence for a wound-strengthening mechanism, not human proof; surgical anastomotic-leak prevention remains governed by technique and standard care. Investigational adjunct only.

In rodent and cell models, 670 nm photobiomodulation repeatedly inhibits the neural and vascular pathology of diabetic retinopathy — Cheng (2018) showed 8 months of daily 670 nm PBM curbed capillary degeneration and permeability in diabetic mice, and Tang (2013) found red light ameliorated DR lesions in vivo while reducing oxidative stress and cell death in vitro. The mechanism (mitochondrial protection, reduced oxidative injury) is coherent and reproducible, but this indication's grounding is animal/in-vitro only, so human DR benefit is a plausible extension to confirm (the sibling DME indication does have human data).

Two controlled canine studies of post-hemilaminectomy recovery disagree: Draper 2012 found dogs given 810 nm LLLT reached ambulation far faster (median 3.5 vs 14 days), while Bennaim 2017 found no difference between PBM, sham-plus-rehab, and sham alone. The conflicting results — likely driven by protocol and dose differences — make this a genuinely mixed picture. PBM is a plausible adjunct in post-operative spinal rehab to confirm with larger trials, not an established one.

Two rabbit studies (Sarveazad 2019, 2021) show 660 nm PBM after sphincterotomy promoted myogenesis, angiogenesis and improved sphincter pressures - most effective when co-applied with chondroitinase ABC or adipose-derived stem cells rather than laser alone. This is preclinical only; it supports a regenerative mechanism worth testing in humans, not an established treatment for anal sphincter injury or fecal incontinence. Parameters were poorly reported in one study.

Two rat studies (Yang 2005, Shao 2005) report that 633 nm He-Ne laser at about 3.36 J/cm2 thickened atrophic gastric mucosa, reduced mucosal inflammation and restored near-normal cell morphology versus untreated controls. This is preclinical evidence using direct (endoscopic-type) mucosal irradiation; it suggests a mechanism but has no human validation, and delivery to the human stomach is non-trivial. Strictly investigational - standard gastritis management (e.g., H. pylori eradication, surveillance) takes precedence.

A rat study (Sert 2021) found polychromatic near-infrared light (600-1200 nm) applied both before and after fat transfer significantly improved graft weight and volume retention (p=0.049, p=0.043), consistent with PBM's pro-angiogenic, anti-inflammatory effects. The dataset's only human entry (Paiva 2024) actually reports survival in head-and-neck cancer patients receiving PBM for oral mucositis - not fat grafting - so on-topic evidence here is animal-only. Treat fat-graft PBM as a plausible preclinical mechanism to confirm in humans, not an established technique.

A well-controlled mouse study delivered four wavelengths at matched fluence (4 J/cm2) and irradiance (10 mW/cm2) and found 635 nm and 810 nm promoted dermal-abrasion healing — with 810 nm best — while 730 nm and 980 nm showed no benefit (Gupta 2014). That wavelength specificity is exactly the kind of mechanistic detail that distinguishes real PBM from generic light exposure. A veterinary study in cownose rays found no clear difference (Gilewski 2024). Preclinical evidence; human translation is a plausible extension to confirm, with wavelength selection clearly important.

Across numerous cell-culture studies and rodent models of hindlimb ischemia, ischemic flaps, and cutaneous wounds, red and near-infrared PBM consistently stimulates new blood-vessel formation (Zhang 2022, Stepanov 2022, Winter 2018, Lim 2011; Huang 2021, Lohr 2013, Dungel 2014, de Sousa 2013). The angiogenic effect is one of the better-supported PBM mechanisms at the bench. Blue light is inconsistent (positive in one rat study, null in another) and green showed a signal in one study. This is preclinical: the mechanism is well-grounded, and human application — accelerating wound and tissue perfusion — is a plausible extension to confirm with controlled human dosing rather than a proven clinical claim.

Across preclinical work, photobiomodulation consistently shifts redox balance toward antioxidant defense — Tonetto (2023) showed six weeks of 660 nm PBM reduced oxidant activity and raised antioxidant capacity in diabetic rats, and a nine-study review (Irber 2026) found uniform modulation of oxidative stress, with lower superoxide and cytochrome c and higher catalase, SOD and glutathione peroxidase. This is solid mechanistic biology, but it speaks to cellular/oxidative stress, not psychological stress; applying it to perceived stress or HPA-axis outcomes is a plausible extension that human studies have not confirmed here.

Across rodent models — diet-induced obesity, aging, and LPS-induced neuroinflammation — transcranial red/NIR light (630-670 nm) repeatedly reduced glial activation (CD68 microglia, GFAP astrocytes) and shifted brain inflammatory cytokines, with correlated memory improvement. The anti-inflammatory signal is consistent and mechanism-aligned. It is entirely preclinical, though, so reduced human neuroinflammation is a biologically reasonable extension to confirm, not a demonstrated outcome.

Building on in-vitro evidence that low-level laser relaxes vascular smooth muscle, an in-vivo study in atherosclerotic Yucatan microswine showed that percutaneous laser light (633 or 1064 nm) reversed histamine-induced arterial vasoconstriction/spasm (Gal 1992). It is a single, older large-animal study, but mechanistically clean and consistent with PBM's nitric-oxide-mediated vasodilation. Human relevance — relieving vasospasm — is a plausible extension to confirm, not an established therapy.

Evidence for auditory neuropathy is preclinical and mixed. In a gerbil model of ouabain-induced auditory neuropathy, 808 nm PBM lowered ABR thresholds and preserved spiral ganglion cells (Lee 2016), but a later mouse/in-vitro study combining stem cells with PBM did not improve hearing or auditory-nerve response (Chang 2023). The neural-rescue mechanism is intriguing, yet with no human data and an inconsistent animal record, human use is a speculative extension to investigate, not a treatment.

For bone density specifically, the available evidence is preclinical: a systematic review of rat studies (de Oliveira 2022) found near-infrared PBM increased new bone formation, osteocytes, osteoblasts, and vascularization, particularly in irradiated-bone healing, though one of six studies showed no difference and parameters varied widely. The mechanism is real and reproducible in animals, but no controlled human bone-density data are presented here - human benefit is a plausible extension to confirm, not an established outcome.

Four rat studies converge that PBM (660, 670, 830 nm) improves transverse rectus abdominis musculocutaneous (TRAM) flap viability - smaller necrotic area, more mast cells, higher VEGF/CD34 and angiogenesis - including under nicotine stress, with 830 nm performing best (das Neves 2016) and effective doses spanning ~6-144 J/cm2. This is consistent preclinical evidence for a pro-angiogenic mechanism, not human proof; flap viability in patients depends on surgical perfusion management. A plausible human adjunct to test.

In a chronic-alcohol mouse model, transcranial 830 nm laser significantly improved cognitive and spatial memory deficits, with histological correlates in the hippocampus. The mechanism — NIR protecting against apoptosis and neuroinflammation while supporting bioenergetics — is well aligned with PBM's known brain effects. This is a single animal study, though: human application is a biologically plausible direction to test, not an established treatment for alcohol-related cognitive impairment.

In a classic mechanistic demonstration, three brief 670 nm LED treatments (4 J/cm2) significantly recovered rod- and cone-mediated retinal function and protected against formate-induced histopathology in methanol-intoxicated rats (Eells 2003). Because methanol's toxic metabolite, formic acid, poisons cytochrome oxidase — exactly the chromophore PBM stimulates — this is one of the cleanest mechanistic stories in the field. It remains animal proof-of-concept; human use is a plausible extension to confirm.

In a controlled rat model of immune-complex lung injury, 650 nm LLLT at 2.6 J/cm² cut the hemorrhagic index and myeloperoxidase activity to a degree not significantly different from celecoxib (Aimbire 2007). It is an intriguing anti-inflammatory/anti-hemorrhagic mechanism signal, but it rests on one animal study. Human application is a plausible extension to confirm, not a therapy — and PBM would be adjunctive only.

In a controlled study of dogs operated for thoracolumbar disk extrusion, those given PBM plus rehab were more likely to improve neurological status (Modified Frankel >3 within 30 days) when deep nociception was preserved on admission (p=0.04), though Kaplan-Meier analysis showed no overall difference in time to recovery (Bruno 2020). So there is a conditional signal tied to baseline severity, within an otherwise mixed/contested literature. PBM is a plausible adjunct in post-op spinal rehab, best viewed as unproven pending larger trials.

In a guinea-pig model of chlamydial inclusion conjunctivitis, water-filtered infrared-A plus visible light (wIRA/VIS) reduced both clinical pathology scores and conjunctival chlamydial load versus untreated infected controls (Inic-Kanada 2020), echoing earlier in-vitro/ex-vivo findings that the irradiation lowers chlamydial infectivity. A genuinely interesting adjunct concept for a blinding neglected disease (trachoma), but it is animal-only — human benefit is a plausible extension to confirm.

In a hemophilia B mouse model, three daily treatments of 650 nm laser (12 J/cm2) accelerated closure of punch-biopsy wounds (10 days vs 13 days in sham, approaching the 9-day wild-type rate) (Hoffman & Monroe 2012). The signal is plausible and consistent with PBM's general wound-healing biology, but it is a single animal study addressing impaired wound healing in hemophilia — not the underlying clotting deficiency. Human application is a plausible extension to confirm; PBM does not and cannot replace factor replacement.

In a mouse and in-vitro study (Yoo 2021), 850 nm PBM restored function of thyroid follicular cells damaged by ionizing radiation, increasing proliferation and cAMP. This is preclinical evidence only - no human trials for radiation-induced thyroid dysfunction - so it establishes a plausible mechanism and a hypothesis worth testing in people, not a proven clinical therapy. Any human application would be an experimental adjunct under endocrinology/oncology supervision.

In a mouse model of complex regional pain syndrome type I, 830 nm PBM applied to the affected paw during the acute phase reduced edema, thermal and mechanical hyperalgesia, and improved gait quality. The anti-inflammatory, pro-analgesic mechanism fits PBM's known biology and the timing (acute-phase, local) is informative. But this is a single animal study — human CRPS application is a biologically reasonable direction to test, not established therapy.

In a mouse model plus in-vitro work (Kim 2019), 633 nm PBM enhanced mesenchymal stem-cell proliferation and self-renewal and, as PBM-preconditioned MSCs, alleviated radiation-induced intestinal mucosal destruction, improved crypt proliferation and barrier function and preserved microvasculature. This is preclinical, mechanism-level evidence - PBM as a cell-priming/angiogenic adjunct - not a human therapy for radiation enteropathy. Strictly investigational.

In a rat hepatic-encephalopathy model (Mendez 2021), transcranial 670 nm PBM (9 J/cm2, daily x7) improved memory deficits comparably to intracranial methylene blue, with both targeting cytochrome c oxidase. This is single-study preclinical evidence establishing a plausible mitochondrial mechanism - not human proof for hepatic encephalopathy, which is managed medically (e.g., lactulose, rifaximin). Any human use would be strictly investigational.

In a rat model (Dos Santos 2021), daily 660 nm PBM reduced the remaining fistula-tract area (248.5 vs 847.2 micrometers^2, p=0.001) and inflammatory infiltrate versus controls, but achieved no complete closure in any animal. This is preclinical, single-study evidence - a plausible mechanism for adjunctive healing, not proof of benefit in human anal fistula, which is surgically managed. Human use would be an experimental adjunct to confirm.

In a veterinary clinical study of seven dogs with noninflammatory alopecia, a multi-wavelength device (470, 685, and 830 nm, 3 J/cm2) applied twice weekly for up to two months increased the area occupied by hair follicles (18% treated vs 11% untreated) and dramatically raised the proportion of haired follicles (93% treated vs 9% control) (Olivieri 2015). It is a single small animal study, but a clean within-subject design with histologic endpoints. Treat as a preclinical/veterinary proof-of-concept; human noninflammatory alopecia application is a plausible extension to confirm.

In aged AC8-overexpressing mice, eight months of full-body PBM (850 nm, 25 mW/cm2, 120 s each weekday) improved a broad panel of cardiovascular aging measures: reduced left-ventricular mass, end-diastolic volume, and aortic stiffness; increased ejection fraction, gait symmetry, and serum TGF-beta1; and raised survival to 100% versus 43% in untreated mice (Syed 2023). This is exactly the kind of full-body, longevity-oriented signal biohackers care about — but it is one mouse study in a genetically modified strain. It is a genuinely exciting hypothesis to test in humans, not a demonstrated human anti-aging effect.

In aged mice with surgery/anesthesia-induced perioperative neurocognitive disorder, transcranial 810 nm light improved cognition and reversed mitochondrial dysfunction, increasing synapse-related protein expression and neuronal survival. The mitochondrial mechanism fits PBM's core biology and targets a condition (post-operative cognitive decline in older patients) with no approved disease-modifying therapy. This is one animal study, so human application is a biologically reasonable direction to test rather than an established intervention.

In animal models, visible/red light has reduced aortic plaque burden (~8% smaller plaque area in Yin 2021, 635 nm, ApoE-/- mice) and raised HDL, and polarized light lowered cholesterol/LDL and atheroma in rabbits (Park 2012). The effect on cholesterol in most settings appears relatively small (Paolillo 2021). This is a plausible cardioprotective mechanism with honest but limited preclinical support — promising enough to study in humans, but not yet a human claim, and certainly not a substitute for statins or lifestyle change.

In bleomycin-induced pulmonary fibrosis models, 660-780 nm PBM reduced inflammatory-cell migration, collagen deposition, and pro-fibrotic TGF-β while upregulating IL-10 from pneumocytes and fibroblasts (de Brito 2019; Brochetti 2017). For a disease as treatment-poor as idiopathic pulmonary fibrosis, that is a mechanistically exciting signal — but it is entirely preclinical. Human anti-fibrotic PBM is a plausible extension to test, not an established therapy, and would only ever be adjunctive to standard IPF care.

In carrageenan-induced pleurisy, 650-660 nm LLLT dose-dependently reduced leukocyte influx, exudation, and inflammatory mediators (NO, IL-6, MCP-1, TNF-α), with effects partly blocked by a cortisol antagonist — implying a glucocorticoid-linked anti-inflammatory pathway (Lopes-Martins 2005/2006; Boschi 2008). The data are consistent and mechanism-revealing, but animal-only. Human pleurisy use would be a plausible extension to confirm and adjunctive at most.

In dogs with degenerative myelopathy — a progressive, fatal neurodegenerative disease with no good treatment — a retrospective review found a higher-power NIR protocol (980 nm, 6-12 W) was associated with significantly slower progression and longer survival than a low-power protocol (904 nm, 0.5 W) or historical controls (Miller 2020). This is a single retrospective veterinary study, so it is a hopeful lead rather than proof, and dose (power) appears pivotal. PBM should be an adjunct within rehabilitation, not a stand-alone therapy.

In estradiol-induced rat PCOS and in cultured PCOS oocytes, photobiomodulation (640-904 nm) has nudged hormone profiles back toward normal, improved oocyte maturation and fertilization, and lowered oxidative stress and apoptosis. This is mechanism-consistent and encouraging, but every data point is animal or in-vitro — there are no human PCOS trials in this evidence set. Treat human application as a plausible, biologically reasonable extension to test, not an established therapy.

In LPS- and MRSA-induced otitis media in rats, dual red/near-infrared LED (655/842 nm) reduced middle-ear mucosal thickening, inflammatory-cell infiltration, and IL-1β/IL-6/TNF-α, and suppressed MRSA biofilm formation. This is a coherent anti-inflammatory, anti-biofilm story — but the evidence is entirely preclinical (rat models plus human/murine cell lines), so framing it as a non-antibiotic option for human ear infection is a plausible extension to confirm, not a proven therapy. PBM here would be an adjunct, never a replacement for indicated antibiotics.

In mouse models of bilateral common carotid artery stenosis and chronic cerebral hypoperfusion, transcranial PBM improved cognition and regional cerebral blood flow and reduced neuronal loss, though residual necrotic foci persisted (Kim 2025; Lee 2019). The honest read: PBM here is a downstream neuroprotective adjunct for the brain suffering from low perfusion — it does not reverse the carotid narrowing itself. Evidence is animal-only and early; human use would be a plausible extension to confirm, framed as brain support, not vascular reopening.

In naturally aged mice (He 2024), 650 nm PBM (4 J/cm2, over 2 months) restored sex-hormone levels, increased primordial and growing follicle counts, improved ovarian angiogenesis and reduced apoptosis, oxidative stress and chronic inflammation. This is single-study preclinical evidence - a compelling mechanism for ovarian rejuvenation to test in humans, not a proven therapy. Human application would be experimental and requires reproductive-medicine oversight.

In rat models of PTSD, photobiomodulation improved or prevented fear- and stress-related behaviors in two studies, while a third found no benefit in blast-injury-related PTSD (Li 2021, Li 2021, Garcia 2021). The mechanistic rationale is real — transcranial near-infrared light reaches cortical and limbic tissue and can modulate mitochondrial function and neuroinflammation — but every data point here is animal, so human PTSD benefit remains a plausible extension to confirm, not an established effect.

In rodent and ram models of testicular damage (diabetes, heat stress, degeneration), localized NIR PBM (808-890 nm) has repeatedly increased Sertoli and Leydig cell counts, lengthened seminiferous tubules, and improved sperm parameters. The repair signal is consistent and mechanism-plausible, but it is entirely animal — human testicular PBM has not been studied here — and one ram study showed high-dose laser (28 J/cm2) could itself injure semen, underscoring a real dose ceiling. Treat human use as an unproven extension to test carefully.

In sepsis-induced acute lung injury models, 650 nm red-light PBM prolonged survival, reduced lung edema and histologic damage, and broadly suppressed pro-inflammatory cytokines and chemokines while reprogramming myeloid responses and preserving mitochondrial function (Zhang 2026); PBM also enhanced mesenchymal-stem-cell therapy for ALI (Chen 2022). The immunometabolic framing is compelling, but the evidence is animal/in-vitro. Human ALI/ARDS use is a plausible extension to confirm, adjunct only.

In three mouse studies of the angiotensin-II apo-E-deficient model, near-infrared PBM (780 nm, ~2 J/cm2, 9 min) both prevented new abdominal aortic aneurysm and halted progression of pre-induced aneurysm (Gavish et al. 2014, 2012, 2009). This is a genuine, reproducible preclinical signal — but it is animal-only, and no human trials exist. Critically, transdermal light cannot reach the aorta, so any human translation would require internal delivery (the authors propose via the femoral artery, abdomen, or transverse colon), making a full-body red-light bed irrelevant for this indication. Treat as a mechanism worth watching, not a usable protocol.

In Walker-256 tumor-bearing rats, 660 nm laser PBM cut paw edema and mechanical hyperalgesia and shifted the local milieu anti-inflammatory — higher IL-10, lower COX-2 and bradykinin-receptor (Bdkrb1) expression (Petrellis 2020). It is a clean mechanistic result for cancer pain, but it is animal-only, so human analgesic use is a plausible extension to confirm — with the added caveat that irradiating tumor tissue itself demands caution (see tumor-growth evidence).

Seven animal studies converge: red/NIR PBM (660, 830, 940 nm) reduced disease-activity index, mucosal inflammation, crypt damage, myeloperoxidase and pro-inflammatory cytokines (and restored colon length and gut-microbiota diversity) in chemically-induced colitis models. The preclinical consistency is genuinely encouraging for a mechanism in inflammatory bowel disease - but there are no human IBD trials here, so this is a plausible extension to test, not a proven therapy. PBM would be an investigational adjunct to standard IBD care, never a replacement.

The available evidence is a single rat study (Bertolini 2011): 830 nm low-level laser reduced pain behavior in a sciatic nerve-compression model. PBM's analgesic and neuro-modulatory mechanism is reasonable for compressive radicular pain, but with only preclinical data presented, human use for sciatica is a plausible extension to test in trials, not a supported clinical recommendation.

The curated evidence describes beneficial effects of PBM in animal models of stroke-induced epilepsy and pentylenetetrazole-induced status epilepticus (Vogel 2020, Tsai 2020). The mechanistic rationale — anti-inflammatory and neuroprotective modulation of hyperexcitable cortex — is reasonable. But this is preclinical only, with no human trials and no extractable trial-level data in our grounding set, so human application is a hypothesis to test, not a treatment.

The flap-surgery evidence base is large but lopsided: about 30 animal studies (rat/mouse/pig) report PBM improving skin/musculocutaneous flap survival via angiogenesis and reduced necrosis, while the single human RCT provided here (Redkin 2017, n=263) actually tested red LED light (625 nm) on the surgical bed during laparoscopic cholecystectomy and found reduced post-surgical ALT/AST/ESR. So human flap-specific RCT evidence is thin; the mechanism is well-supported preclinically. Promising as a surgical adjunct to confirm in human flap trials, not an established protocol.

The only evidence here is a veterinary RCT (Tambella 2020) in dogs: a topical LED-illuminated chromophore gel (blue 440-460 nm fluorescence) produced positive clinical effects in canine otitis externa, comparable to standard antibiotic/antifungal care. This is preclinical/veterinary and uses fluorescent blue-light biomodulation rather than classic red/NIR PBM, so human ear-canal use is a speculative extension to study, not an established treatment.

Two mouse studies suggest PBM dampens the allergic arm of contact dermatitis: He-Ne 633 nm (12.2 J/cm2) decelerated allergic contact dermatitis, particularly when applied before challenge, while having essentially no effect on irritant contact dermatitis (Sakihama 1995); a 2024 study found PBM suppressed T-cell activation in an allergic contact dermatitis model via the TGF-beta pathway (Fu 2024). The mechanism is coherent and the immunomodulatory direction is consistent, but this is animal-only — human use is a plausible extension to confirm, not an established treatment.

Two rabbit studies found that pretreating the filtration site with 633 nm He-Ne laser before trabeculectomy reduced scar formation, downregulating connective-tissue growth factor (CTGF), PCNA and collagen synthesis in fibroblasts (Wang 2010; Hu 2010). It is a coherent antifibrotic rationale for improving bleb survival — the perennial failure mode of glaucoma filtration surgery — but the evidence is animal-only, so human translation is a plausible extension to confirm.

Two rat studies (Marinho 2013, 2014) found PBM - 780 nm alone or 780+660 nm combined - reduced neutrophil infiltration and myeloperoxidase and improved reparative collagenization in nasogastric-intubation-induced reflux laryngitis. This is consistent preclinical evidence for an anti-inflammatory mechanism, not human proof; laryngopharyngeal reflux in people is managed by reflux control and ENT care. Investigational adjunct only.

Animal studies show transcranial PBM improves memory and reduces neuroinflammation in aging-brain models, and human work generally reports good tolerability with measurable cortical effects. But two honest brakes apply: a penetration review (Salehpour 2019) shows only ~0.2-10% of transcranial light reaches the human brain — far less than in rodents — and a 2025 case report described a poor neurological outcome after PBM-helmet-induced vasodilation in a patient with a vertebral-artery dissection. So the anti-aging brain signal is real but unproven in humans, and not risk-free in vascular-compromised patients.

A bidirectional cohort of 201 hyperopic children found low-level LED red-light therapy significantly accelerated axial elongation (interaction beta=+0.082 mm/year, p<0.001), with treated eyes outgrowing untreated fellow eyes in anisometropic children (Li 2026). For hyperopia per se, faster axial growth reduces the hyperopic error — but the same growth-promoting effect is exactly the safety concern that makes uncontrolled red-light use risky. Treat this as a single observational signal that cuts both ways, not an endorsement.

A single open-label study (Maiello 2019, n=15) reported a large reduction in clinician-rated anxiety (SIGH-A, Cohen's d ≈ 1.47) after transcranial PBM, suggesting real anxiolytic potential consistent with PBM's prefrontal mitochondrial mechanism. But this is one small uncontrolled study with no sham comparison, so the effect could be partly expectancy. It is an encouraging early lead worth a controlled trial — and only an experimental adjunct to evidence-based anxiety care for now.

The stated reason the order runs magnetism, then oxygen, then light, that PEMF opens the cell and alkalizes the terrain so oxygen is taken up better, and that the resulting oxygen surplus makes light therapy more effective, is an operator and manufacturer explanation. No study has measured whether prior PEMF changes oxygen uptake during subsequent exercise, or whether prior hyperoxia changes the response to subsequent photobiomodulation.

The Superhuman Protocol sequence of PEMF, then exercise with oxygen, then red light photobiomodulation has no published trial testing it as a sequence. Every citation offered for it is a single-modality study, so any claim of combined or additive benefit is a vendor rationale rather than a research finding.

Direct human evidence that PBM aids hemostasis is essentially absent. A rat bioinformatics study (Arjmand 2021) implicated fibrinogen and plasminogen pathways, and a 2025 review describes red/NIR/far-infrared effects on nitric oxide, endothelial function, platelet aggregation, and microvascular perfusion mapped onto Virchow's triad. Importantly, the review itself flags controversy - some apparent benefit may simply reflect excluding pro-thrombotic blue light - plus unresolved tissue-penetration and protocol-standardization gaps. This is a mechanistically intriguing, preclinical-only story; human use is a plausible extension to test in RCTs, not a current recommendation.

Honesty matters most here: the one human glaucoma trial reporting large IOP drops (-39.7%) and visual-field gains (Ivandic 2015) has been RETRACTED, so it cannot anchor any clinical claim. What remains is mechanistic — in-vitro work showing red/NIR light raises trabecular-meshwork outflow facility (Roberts 2007) and a review describing red light boosting cytochrome c oxidase and reducing retinal-ganglion-cell inflammation while blue light harms them (Ahn 2023). The rationale for neuroprotection/IOP modulation is real, but human efficacy is unproven and should not be claimed on this evidence.

In a rabbit model with vocal-fold fibroblast experiments, 635 nm PBM (8 J/cm²) inhibited inflammation, boosted hyaluronic-acid secretion, and reduced collagen deposition, regenerating vocal-fold tissue without scar — a clean preclinical wound-healing signal. Direct human evidence for wound healing is lacking; the available human RCT tested PBM on vocal load (not wounds) and found only discreet acoustic effects. So accelerated, scarless vocal-fold repair in people is a plausible extension to confirm, and PBM should be considered an adjunct to surgical/voice care, not a proven post-injury treatment.

Photobiomodulation has a credible neuroprotective rationale in acute ischemic stroke — near-infrared light reaching the penumbra can support mitochondrial ATP output and blunt oxidative and excitotoxic injury. However, the grounding attached to this indication actually demonstrates PBM's neuromodulatory and analgesic effects (Pigatto 2017 and de Sousa 2018 in rodents; Reuss 2021 and Takeuchi 2026 raising human pain thresholds), not direct acute-stroke recovery outcomes. Human acute-stroke benefit therefore remains unproven on this evidence set and should be treated as a plausible mechanistic extension to confirm in stroke-specific trials.